A gene therapy is teaching the heart to repair itself after a heart attack
When a heart attack strikes, heart muscle dies — and it doesn’t grow back.
The protein is called NPPA, also known as atrial natriuretic peptide. It’s naturally produced by heart cells and plays a role in regulating blood pressure and fluid balance. But researchers discovered that NPPA also stimulates heart cells to divide — a remarkable property, since cardiac muscle tissue has an exceptionally low regenerative capacity. In adult mammals, the heart is almost entirely incapable of repairing itself after injury.
The therapy uses an elegant mechanism: a small amount of genetic material is injected into fat cells, which then act as miniature factories, continuously secreting NPPA into the bloodstream. This sidesteps one of the major technical obstacles in cardiac gene therapy: delivering genetic material directly into heart cells is difficult and risky. Using fat tissue as the delivery platform requires a much lower dose and carries fewer complications.
The stubborn problem of the non-regenerating heart
Heart attacks are among the leading causes of death worldwide. Survival rates have improved dramatically thanks to better acute care, but the damage left behind — dead heart muscle replaced by scar tissue — leads to heart failure over time. That process is gradual but relentless: the heart pumps less efficiently, becomes overloaded, and eventually fails. Heart failure is one of the largest causes of hospitalization and death in older adults.
Existing treatments — medications, pacemakers, transplants — manage the consequences without reversing the damage. Regenerative approaches, including stem cell therapies, have largely disappointed in clinical trials. The NPPA approach is different: rather than introducing new cells, it stimulates existing heart cells to divide and replenish lost tissue.
Promising, but still early
The results so far come from animal models. In mice and rats, the treatment produced measurable increases in heart cell division and improved cardiac function following induced heart attacks. Whether this translates to humans remains unknown. Human heart cells divide far less readily than those of mice — meaning the threshold to induce division is likely much higher, and represents a genuine obstacle.
Still, the technical platform — fat tissue as a vehicle for sustained protein secretion — has broad potential. Other research groups are pursuing similar strategies for different proteins and different conditions. If the platform proves effective, its implications extend well beyond heart patients, into the wider landscape of age-related degenerative disease.